EP2275106A1 — Combination drug containing probucol and a tetrazolylalkoxy-dihydrocarbostyril derivative with superoxide supressant effects
Assigned to Otsuka Pharmaceutical Co Ltd · Expires 2011-01-19 · 15y expired
What this patent protects
This invention relates to a combination drug comprising a combination of a tetrazolylalkoxy-dihydrocarbostyril derivative of the formula: wherein R is cycloalkyl, A is lower alkylene, and the bond between 3-and 4-positions of carbostyril nucleus is single bond or double bon…
USPTO Abstract
This invention relates to a combination drug comprising a combination of a tetrazolylalkoxy-dihydrocarbostyril derivative of the formula: wherein R is cycloalkyl, A is lower alkylene, and the bond between 3-and 4-positions of carbostyril nucleus is single bond or double bond, or a salt thereof and Probucol, which is useful for preventing and treating cerebral infarction including acute cerebral infarction and chronic cerebral infarction, arteriosclerosis, renal diseases (e.g. diabetic nephropathy, renal failure, nephritis), and diabetes owing to synergistic superoxide suppressant effects of the combination.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.